Global Immuno Oncology Assays Market Size study & Forecast, by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics

The Global Immuno Oncology Assays Market, valued at approximately USD 6.26 billion in 2024, is poised to expand at a remarkable CAGR of 12.50% during the forecast period from 2025 to 2035. Immuno-oncology assays, which serve as the backbone of precision cancer research and clinical diagnostics, are pivotal in evaluating immune responses, identifying predictive biomarkers, and guiding personalized therapy decisions. These assays enable clinicians and researchers to gain deeper insights into the complex interplay between the immune system and tumors, allowing for the development of targeted treatments that significantly enhance patient survival outcomes. Market growth is being accelerated by the rising global cancer burden, the rapid adoption of precision medicine, and continuous advancements in molecular diagnostic technologies. Additionally, the expanding application of next-generation sequencing (NGS) and highly sensitive immunoassays is unlocking new opportunities for biomarker discovery and companion diagnostics in oncology.

The upward trajectory of the market is further propelled by a surge in clinical trials evaluating novel immunotherapies, particularly immune checkpoint inhibitors and CAR-T cell therapies. As pharmaceutical companies and research institutions intensify their R&D investments, there is a parallel need for robust, reproducible, and high-throughput assay platforms to monitor therapeutic efficacy and detect resistance mechanisms. For instance, the integration of PCR and NGS into immuno-oncology workflows has enabled the detection of minute genetic alterations and immune signatures that inform treatment strategies with unprecedented accuracy. While these innovations are transforming cancer care, the high cost of advanced assay platforms and regulatory complexities surrounding biomarker validation may pose temporary hurdles, particularly in emerging markets. Nevertheless, ongoing collaborations between diagnostic developers, biotech firms, and healthcare providers are expected to mitigate these barriers and expand global accessibility.

Regionally, North America holds the lion’s share of the market, fueled by a mature healthcare infrastructure, strong biotechnology presence, and an extensive network of oncology research centers. The United States, in particular, benefits from robust funding for cancer research, a high concentration of key industry players, and favorable regulatory frameworks that encourage innovation in diagnostics. Europe follows closely, driven by cross-border collaborations in cancer genomics, public health initiatives to improve early cancer detection, and the integration of molecular diagnostics into national healthcare systems. Meanwhile, Asia Pacific is anticipated to experience the fastest growth through 2035, owing to rapid advancements in healthcare infrastructure, rising cancer prevalence in countries like China and India, and increasing participation in global oncology research initiatives. Furthermore, expanding diagnostic capabilities in Latin America and the Middle East & Africa are creating emerging opportunities for assay adoption, particularly as these regions scale up their precision medicine programs.

Major market player included in this report are:
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Qiagen N.V.
• BD (Becton, Dickinson and Company)
• PerkinElmer, Inc.
• Merck KGaA
• Abbott Laboratories
• Danaher Corporation (Cytiva & Beckman Coulter Life Sciences)
• Guardant Health, Inc.
• NanoString Technologies, Inc.
• Adaptive Biotechnologies Corporation
• Sysmex Corporation

Global Immuno Oncology Assays Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product & Service:
• Consumables
• Instruments
• Software

By Technology:
• PCR
• NGS
• Immunoassay

By Cancer Indications:
• Lung
• Breast
• Colorectal
• Bladder
• Melanoma

By Application:
• Research
• Diagnostics

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe (ROE)

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific (RoAPAC)

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more